C-5EF1targeted calcification reversal, elastin targeting, bioengineering
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Elastrin Therapeutics targeted calcification reversal, elastin targeting, bioengineering
Elastrin Therapeutics is focused on reversing arterial hardening caused by calcification, a driver of heart attacks, stroke, peripheral artery disease, and limb loss. Its platform delivers therapy directly to sites of calcification without invasive surgery or lifelong drugs. The company states that the same targeting platform can address multiple cardiovascular and age-related conditions.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Elastrin Therapeutics — Early mechanism · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic